INV4
1月前
Biorestorative Therapies (BRTX)
Updated May 28, 2026
Price Target
Based on short-term price targets offered by two analysts, the average price target for Biorestorative Therapies, Inc. comes to $8.00. The forecasts range from a low of $1.00 to a high of $15.00. The average price target represents an increase of 1760.47% from the last closing price of $0.43.
Broker Rating
Biorestorative Therapies, Inc. currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Date | Brokerage | Analyst | Current rating | Price target* | Upside | Previous rating | Rev price target*
2/20/26 | Maxim Group | Michael Okunewitch | Strong Buy | $1 | 108.77% | Strong Buy | $8
2/12/26 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | $15 | 3,031.52% | Strong Buy | $18
10/15/25 | Zacks Research | Research Team | Hold | NA | NA | Hold | NA
https://www.zacks.com/stock/research/BRTX/price-target-stock-forecast
* Price targets are not always met
=====================
Number of Insider Shares Traded
Insider Trade | 3 Months | 12 Months
Number of Shares Bought | 0 | 27,344
Number of Shares Sold | 0 | 0
Total Shares Traded | 0 | 27,344
Net Activity | 0 | 27,344
https://www.nasdaq.com/market-activity/stocks/brtx/insider-activity
=====================
BRTX Institutional Holdings
Ownership Summary
Institutional Ownership | 3.01% (plus most recent 4.9% stake: Kaos Capital)* = 7.91%
Total Shares Outstanding (millions) | 25
Active Positions | Holders | Shares
Increased Positions | 7 | 514,367 (this number is without the most recent +4.9% stake: Kaos Capital)*
Decreased Positions | 4 | 75,644
Held Positions | 7 | 175,886
Total Institutional Shares | 18 | 765,897 (without the most recent +4.9% stake: Kaos Capital)*
https://www.nasdaq.com/market-activity/stocks/brtx/institutional-holdings
*MOST RECENT:
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders
MIAMI, May 27, 2026 /CNW/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").
This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.
Unfortunately, BRTX shareholders are not currently gaining meaningful value from the existing business. We at Kaos feel that the Company should explore a comprehensive strategic review and consider a pivot into a broader range of AI opportunities.
As a significant shareholder, Kaos Capital is committed to working constructively with the BRTX Board of Directors and management to unlock shareholder value. To that end, we intend to seek an immediate meeting with the Board to discuss the Company's strategy, operations, corporate governance, and potential pathways—including a possible pivot into AI—to enhance value for all shareholders.
We look forward to engaging in a productive dialogue that prioritizes the best interests of BRTX and its shareholders.
About Kaos Capital
Kaos Capital Ltd. is a Miami-based hedge fund with offices in The Bahamas and Toronto, specializing in activist investing, primarily in the Canadian and U.S. markets. Led by Adam Arviv, Kaos Capital seeks to partner with management teams and boards to drive operational improvements and strategic initiatives that maximize long-term shareholder value.
Link article
$BRTX 🗞️
INV4
1月前
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
May 26, 2026
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment.
MELVILLE, N.Y., May 26, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that the last patient has been dosed in its fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease (cLDD), completing treatment administration in the Company’s lead clinical program and advancing the study into the next stage of blinded follow-up ahead of expected topline safety and efficacy data in Q2 2027.
The prospective, randomized, double-blind, sham-controlled, single-disc Phase 2 study enrolled approximately 99 patients across U.S. clinical sites and is designed to evaluate the safety and preliminary efficacy of BRTX-100 in patients with painful chronic lumbar disc disease. Subjects were randomized in a 2:1 ratio to receive either BRTX-100 or control treatment. The primary safety endpoints for the trial include the frequency and severity of adverse events and serious adverse events, as well as imaging-related findings. The primary efficacy responder endpoint is defined as at least a 30% improvement from baseline in both pain -- as measured by the Visual Analog Scale -- and function --as measured by the Oswestry Disability Index, at week 52. Study follow-up assessments are being conducted at weeks 2, 12, 26, 52 and 104, with MRI evaluations at baseline, week 52 and week 104.
“Completion of dosing in our Phase 2 BRTX-100 trial represents an important transition point for BioRestorative,” said Lance Alstodt, BioRestorative Chief Executive Officer. “We have now completed treatment administration in a rigorously designed, randomized, double-blind, sham-controlled study of our lead regenerative spine candidate, and the program is moving through blinded follow-up toward the 52-week efficacy assessment and expected topline safety and efficacy data in the second quarter of 2027. Importantly, this milestone also comes as we continue Phase 3 readiness activities following our Type B meeting with the FDA, where the agency did not raise clinical safety concerns and provided alignment on key elements of the late-stage development pathway.
“With Phase 2 dosing now complete, we believe BioRestorative is positioned to advance the next phase of BRTX-100 development while reducing expenses and redirecting operational focus and resources toward additional value-creation priorities, including the continued commercialization of our BioCosmeceutical platform,” Mr. Alstodt continued. “Our objective is to build from this milestone with discipline, clinical rigor and a clear focus on advancing our regenerative medicine platform across both therapeutic and commercial opportunities.”
BRTX-100 is BioRestorative’s proprietary autologous, hypoxically cultured mesenchymal stem cell therapy designed for delivery into the harsh, low-oxygen, low-nutrient environment of the intervertebral disc. Patients in the trial received a single intradiscal injection of BRTX-100 consisting of 40 x 10^6 cells administered in approximately 1.5 cc through a minimally invasive outpatient procedure.
Eligible patients enrolled in the study were required to have chronic low back pain persisting for at least six months, failure of conservative therapy for at least six months, MRI-confirmed single symptomatic lumbar disc disease and minimum baseline pain and disability thresholds. Major exclusion criteria included prior lumbar surgery at the index level and prior biologic or cellular disc interventions.
BioRestorative has previously reported favorable blinded safety and preliminary efficacy data from the ongoing Phase 2 trial, including sustained improvements in pain and functional measures across multiple follow-up periods and MRI findings suggestive of potential disc remodeling in certain subjects. In previously disclosed blinded datasets, the Company reported clinically meaningful improvements across pain and function measures, including Visual Analog Scale, Oswestry Disability Index, Roland-Morris Disability Questionnaire and Functional Rating Index assessments. To date, the Company has reported no dose-limiting toxicities or serious adverse events related to BRTX-100 in the safety cohorts evaluated. These blinded findings have been presented at scientific and industry conferences and disclosed through prior Company announcements.
BRTX-100 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of chronic lumbar disc disease. BioRestorative previously announced a positive outcome from a Type B meeting with the FDA regarding key elements of a potential Phase 3 program and a pathway toward future BLA-enabling activities. The Company expects to continue advancing Phase 3 preparation activities while blinded follow-up in the Phase 2 study continues, with topline safety and efficacy data expected in Q2 2027.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial products are formulated and manufactured in our cGMP, ISO-7 certified clean room facility. Each product features a cell-based secretome enriched with exosomes, proteins, growth factors, peptides, and other carefully selected active ingredients. This proprietary biologic portfolio has been thoughtfully engineered to support skin health and longevity while addressing visible signs of aging and enhancing overall cosmetic performance. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space
Link article
$BRTX 🗞️
INV4
1月前
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
May 27, 2026
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders
MIAMI, May 27, 2026 /CNW/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").
This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.
Unfortunately, BRTX shareholders are not currently gaining meaningful value from the existing business. We at Kaos feel that the Company should explore a comprehensive strategic review and consider a pivot into a broader range of AI opportunities.
As a significant shareholder, Kaos Capital is committed to working constructively with the BRTX Board of Directors and management to unlock shareholder value. To that end, we intend to seek an immediate meeting with the Board to discuss the Company's strategy, operations, corporate governance, and potential pathways—including a possible pivot into AI—to enhance value for all shareholders.
We look forward to engaging in a productive dialogue that prioritizes the best interests of BRTX and its shareholders.
About Kaos Capital
Kaos Capital Ltd. is a Miami-based hedge fund with offices in The Bahamas and Toronto, specializing in activist investing, primarily in the Canadian and U.S. markets. Led by Adam Arviv, Kaos Capital seeks to partner with management teams and boards to drive operational improvements and strategic initiatives that maximize long-term shareholder value.
Link article
$BRTX 💹
US Market News
1月前
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)May 27, 2026 7:45 AM
PR Newswire (US) Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholdersMIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based hedge fund focused on activist investing, today announced that it has acquired 4.9% of the issued and outstanding common stock of BioRestorative Therapies, Inc. ("BRTX" or the "Company").This ownership stake was acquired in the open market through normal course stock purchases. Kaos Capital believes that BRTX represents a compelling opportunity, as the public vehicle may be better positioned for a strategic pivot into the AI space.Unfortunately, BRTX shareholders are not currently gaining meaningful value from the existing business. We at Kaos feel that the Company should explore a comprehensive strategic review and consider a pivot into a broader range of AI opportunities.As a significant shareholder, Kaos Capital is committed to working constructively with the BRTX Board of Directors and management to unlock shareholder value. To that end, we intend to seek an immediate meeting with the Board to discuss the Company's strategy, operations, corporate governance, and potential pathways—including a possible pivot into AI—to enhance value for all shareholders.We look forward to engaging in a productive dialogue that prioritizes the best interests of BRTX and its shareholders.About Kaos CapitalKaos Capital Ltd. is a Miami-based hedge fund with offices in The Bahamas and Toronto, specializing in activist investing, primarily in the Canadian and U.S. markets. Led by Adam Arviv, Kaos Capital seeks to partner with management teams and boards to drive operational improvements and strategic initiatives that maximize long-term shareholder value.Cautionary NoteThis announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. All investments involve risk, and past performance is not indicative of future results. Shareholders should consult their own advisors regarding their individual circumstances. View original content:https://www.prnewswire.com/news-releases/kaos-capital-announces-acquisition-of-4-9-stake-in-biorestorative-therapies-nasdaq-brtx-302782386.htmlSOURCE KAOS Capital Original: Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
West2
4月前
$BRTX Recently, there has been a shift towards providing access to non-FDA-approved stem cell therapies for patients suffering from numerous musculoskeletal conditions, particularly back pain. Although not covered by insurance, states such as Utah, Wyoming, Texas, and Florida have instituted state laws that allow providers to offer therapies, such as BRTX-100, to patients. We intend to seek strategic and commercial partnerships within these states, which would allow us to potentially commercialize BRTX-100 prior to full BLA approval.
INV4
5月前
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
Feb 24, 2026
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.”
The newly allowed patent application provides the broadest protection obtained for BioRestorative’s allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem® technology, designed to treat obesity and metabolic disorders. The claims covered are: a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.
With this allowance, BioRestorative is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, which continue to be one of the fastest-growing therapeutic categories in the world.
“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem®.”
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
https://investorshub.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/97901776/biorestorative-expands-global-protection-for-therm
$BRTX 🗞️
INV4
5月前
BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform
Feb 24, 2026
BioRestorative Therapies, Inc. (NASDAQ:BRTX) said Tuesday that Australia’s intellectual property authority has approved a key patent application covering its ThermoStem® technology, expanding global protection for the company’s stem cell–based treatment approach targeting obesity and metabolic disorders.
The allowance, granted by IP Australia under Patent Application No. 2020265664, relates to “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.” The patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) platform, including methods for producing non-naturally occurring three-dimensional stem cell aggregates.
The company said the development strengthens intellectual property coverage for ThermoStem®, which is being advanced as a potential next-generation, cell-based alternative to GLP-1 therapies — one of the fastest-expanding segments in the global pharmaceutical market.
BioRestorative believes its approach could offer longer-lasting therapeutic effects while improving safety and dosing flexibility compared with existing GLP-1 drugs.
“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem®.”
The newly allowed patent adds to BioRestorative’s expanding international intellectual property portfolio as the company continues clinical development of regenerative medicine therapies.
About BioRestorative Therapies, Inc.
BioRestorative Therapies develops therapeutic products based on cell and tissue engineering protocols, primarily using adult stem cells. Its core clinical programs focus on treatments for spinal and disc disease as well as metabolic disorders, alongside a commercial BioCosmeceutical platform.
https://investorshub.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/97903145/biorestorative-secures-australian-patent-protectio
$BRTX 🗞️
iHub News
5月前
BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platformFebruary 24, 2026 10:14 AM
IH Market News
BioRestorative Therapies, Inc. (NASDAQ:BRTX) said Tuesday that Australia’s intellectual property authority has approved a key patent application covering its ThermoStem® technology, expanding global protection for the company’s stem cell–based treatment approach targeting obesity and metabolic disorders.The allowance, granted by IP Australia under Patent Application No. 2020265664, relates to “Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same.” The patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) platform, including methods for producing non-naturally occurring three-dimensional stem cell aggregates.The company said the development strengthens intellectual property coverage for ThermoStem®, which is being advanced as a potential next-generation, cell-based alternative to GLP-1 therapies — one of the fastest-expanding segments in the global pharmaceutical market.BioRestorative believes its approach could offer longer-lasting therapeutic effects while improving safety and dosing flexibility compared with existing GLP-1 drugs.“As we continue our mission to advance cell-based therapeutic candidates that may offer the potential for longer-lasting efficacy with improved safety and dosing advantages over GLP-1 drugs, we remain focused on building our global patent protection to strengthen our competitive moat in obesity and related metabolic diseases, and on bolstering our position as a leader in the stem cell-based therapies and products space,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent application to our growing global IP portfolio underscores our commitment and belief in the incredible potential of ThermoStem®.”The newly allowed patent adds to BioRestorative’s expanding international intellectual property portfolio as the company continues clinical development of regenerative medicine therapies.About BioRestorative Therapies, Inc.
BioRestorative Therapies develops therapeutic products based on cell and tissue engineering protocols, primarily using adult stem cells. Its core clinical programs focus on treatments for spinal and disc disease as well as metabolic disorders, alongside a commercial BioCosmeceutical platform.BioRestorative Therapies stock price
Original: BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform
Hole shot King
7月前
508,592 Shares of Common Stock
This prospectus relates to the offer and sale from time to time of up to 508,592 shares of common stock, par value $0.0001 per share, of BioRestorative Therapies, Inc. by the selling securityholders listed under the caption “Selling Securityholders” on page 7 of this prospectus (the “selling securityholders”). All of the shares being offered, when sold, will be sold by the selling securityholders or their respective pledgees, donees, assignees, transferees or other successors-in-interest. We are filing the registration statement of which this prospectus is a part to fulfill a contractual obligation to do so, as described in this prospectus. We will not receive any of the proceeds from the sale or other disposition of the shares by the selling securityholders.
The selling securityholders or their respective pledgees, donees, assignees, transferees or other successors-in-interest may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of our common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices relating to the prevailing market price, at varying prices determined at the time of sale or at negotiated prices. See “Plan of Distribution” for additional information.
Our common stock is currently traded on the NASDAQ Capital Market under the symbol “BRTX.” On December 10, 2025, the closing sale price for our common stock on the NASDAQ Capital Market was $1.10 per share.
Investing in our common stock involves risks. You should carefully read the section entitled “Risk Factors” on page 3 of this prospectus before purchasing any shares of common stock offered by this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
This prospectus is dated December 10, 2025.
https://investorshub.advfn.com/stock-market/NASDAQ/biorestorative-therapies-BRTX/stock-news/97434029/form-424b3-prospectus-rule-424b3
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
TheBurn
3週前
glenn1919
1月前
ErnieBilco
5月前
AKAPAK
5月前
I ll be back
1年前
メールアドレスで登録
